4.6 Article

Preoperative Beta-Blocker Usage: Is It Really Worthy of Being a Quality Indicator?

期刊

ANNALS OF THORACIC SURGERY
卷 92, 期 3, 页码 788-795

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.athoracsur.2011.03.088

关键词

-

向作者/读者索取更多资源

Background. Since 2007, the use of preoperative beta-blockers has been used as a quality standard for patients undergoing coronary artery bypass graft surgery. Recent studies have called into question of the benefit of empiric preoperative beta-blocker use. Methods. Data were extracted from our Society of Thoracic Surgeons certified database for patients undergoing isolated coronary artery bypass graft surgery from 2000 to 2008. We compared the outcomes for patients who received preoperative beta-blockers with those of patients who did not. Results. The study group had 12,855 patients, of whom 7,967 (62.0%) were treated preoperatively with beta-blockers. Using propensity matching, we selected two matched groups of 4,474 patients with preoperative beta-blocker use and 4,474 not using preoperative beta-blockers. In the unmatched cohort, only deep sternal infection (0.3% versus 0.5% without beta-blockers; p = 0.032), pneumonia (1.9% versus 2.4% without beta-blockers; p = 0.039), and intraoperative blood usage (37.2% versus 34.1% without beta-blockers; p < 0.001) reached statistically significant difference. In the matched groups, there was no difference between adverse event rates in patients treated with beta-blockers and those who were not. The number of patients requiring intraoperative blood product use was significantly higher among beta-blocker-treated patients (p = 0.004). Calculating the adjusted odds ratios showed that in the matched groups, the preoperative use of beta-blockers was not an independent predictor of mortality. Conclusions. A rational for preoperative beta-blockade exists. However, as with any medical intervention, its application should be tailored to specific clinical scenarios. With no differences in mortality or morbidity, our findings do not support preoperative beta-blockade as a useful quality indicator for coronary artery bypass graft surgery. (Ann Thorac Surg 2011;92:788-96) (C) 2011 by The Society of Thoracic Surgeons

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据